TY - JOUR
T1 - Clinical use of insulin degludec
AU - Vora, Jiten
AU - Cariou, Bertrand
AU - Evans, Marc
AU - Gross, Jorge Luiz
AU - Harris, Stewart
AU - Landstedt-Hallin, Lena
AU - Mithal, Ambrish
AU - Rodriguez, Martín Rodríguez
AU - Meneghini, Luigi
N1 - Funding Information:
JV has served on advisory boards and received support for research and attendance for national and international educational meetings and honoraria for lecturing from Novo Nordisk, Lilly, Sanofi, MSD, Takeda, Novartis and Abbott. AM has served on advisory boards and received speaker fees from Novo Nordisk, Sanofi, Novartis, Lilly, MSD, Boehringer Ingelheim, Bristol Myers Squibb and AstraZeneca. He has conducted clinical trials for Novo Nordisk, Sanofi, MSD and Boehringer Ingelheim. LM has performed research, served on advisory boards or provided consultation for Novo Nordisk, Sanofi, Halozyme Therapeutics, Boehringer Ingelheim, Pfizer and MannKind. ME has served as an advisory panel member for Novo Nordisk, Novartis, MSD and Sanofi, and received research support from Novo Nordisk. LLH has served on advisory boards and provided consultation for Novo Nordisk, and received lecture fees from Novo Nordisk, Sanofi, Bayer, MSD and Lilly. SH has received funding for research from Sanofi, Novo Nordisk, Janssen and AstraZeneca. He has served on advisory boards and provided consultation for Novo Nordisk, BI/Lilly, AstraZeneca-BMS, Sanofi, Merck, and Janssen. JLG has received grants and/or research support from Boehringer Ingelheim, Eli Lilly, GSK, Mannkind Corporation and Novo Nordisk. He has also provided consultation or served as a member of scientific advisory panels and speaker bureaux for Boehringer Ingelheim, Eli Lilly and Novo Nordisk. BC has served on advisory panels for Eli Lilly, Genfit, Novo Nordisk and Sanofi and received grants/research support from Novo Nordisk and Sanofi. MR has served as a speaker for Novo Nordisk, Sanofi, Novartis, AstraZeneca, Bristol Myers Squibb and Eli Lilly. He has also served as an advisory board member for Novo Nordisk, AstraZeneca-BMS and Sanofi .
Funding Information:
Medical writing assistance was provided by apothecom scopemedical ltd, UK, funded by Novo Nordisk UK Research Foundation .
Publisher Copyright:
© 2015 The Authors.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ~25. h and a duration of action >42. h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily. Evidence from phase 3a clinical trials with a treat-to-target design in patients with type 1 and type 2 diabetes has shown that IDeg has similar efficacy to IGlar, with a 9% and 26% reduction in risk of overall and nocturnal hypoglycaemia, respectively (in the pooled population) during the entire treatment period, and a 16% and 32% reduction during the maintenance period, respectively. Given its pharmacodynamic properties, IDeg offers a broad dosing window, allowing for flexible dose administration, if required. Two different formulations of IDeg are available (100. units/mL [U100] and 200. units/mL), the latter providing the same IDeg dose as the U100 formulation in half the injection volume. The unique pharmacokinetic profile of IDeg facilitates glycaemic control while minimising the risk of nocturnal hypoglycaemia.
AB - The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ~25. h and a duration of action >42. h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily. Evidence from phase 3a clinical trials with a treat-to-target design in patients with type 1 and type 2 diabetes has shown that IDeg has similar efficacy to IGlar, with a 9% and 26% reduction in risk of overall and nocturnal hypoglycaemia, respectively (in the pooled population) during the entire treatment period, and a 16% and 32% reduction during the maintenance period, respectively. Given its pharmacodynamic properties, IDeg offers a broad dosing window, allowing for flexible dose administration, if required. Two different formulations of IDeg are available (100. units/mL [U100] and 200. units/mL), the latter providing the same IDeg dose as the U100 formulation in half the injection volume. The unique pharmacokinetic profile of IDeg facilitates glycaemic control while minimising the risk of nocturnal hypoglycaemia.
KW - Clinical practice
KW - Diabetes
KW - Dosing
KW - Hypoglycaemia
KW - Insulin
KW - Insulin degludec
UR - http://www.scopus.com/inward/record.url?scp=84930818009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930818009&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2015.04.002
DO - 10.1016/j.diabres.2015.04.002
M3 - Review article
C2 - 25963320
AN - SCOPUS:84930818009
SN - 0168-8227
VL - 109
SP - 19
EP - 31
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
IS - 1
ER -